Table A3.

PFS by Prognostic Factors and Cytogenetic Subgroups

Characteristic	No. of Patients	PFS (days)		Patient Status After 30-Month Follow-Up
				No Event		PD		Dead		Lost to Follow-Up
		Median	95% CI	No.	%	No.	%	No.	%	No.	%
Binet stage
B	44	650	359 to 849	14	31.8	28	63.6	2	4.5	0	0.0
C	56	720	477 to 817	17	30.4	33	58.9	5	8.9	1	1.8
Age, years
< 65	28	659	374 to NE	10	35.7	18	64.3	0	0.0	0	0.0
≤ 65	72	720	477 to 798	21	29.2	43	59.7	7	9.7	1	1.4
Responders
CR/PR	84	730	660 to 849	29	34.5	49	58.3	5	6.0	1	1.2
Nonresponders	15	255	85 to 366	2	13.3	12	80.0	1	6.7	0	0.0
IgVH status
Mutated	36	738.5	374 to 1,038	14	38.9	18	50.0	3	8.3	1	2.8
Normal	52	690.5	359 to 730	11	21.2	40	76.9	1	1.9	0	0.0
17p deletion status
Deleted	0	NE		NE		NE		NE		NE
Normal	86	727	545 to 817	29	33.7	53	61.6	3	3.5	1	1.2
11q deletion status
Deleted	13	359	255 to 717	1	7.7	12	92.3	0	0.0	0	0.0
Normal	76	730	545 to 913	28	36.8	44	57.9	3	3.9	1	1.3
12q trisomy status
+12q	16	1,038	545 to 1,038	9	56.3	6	37.5	1	6.3	0	0.0
Normal	73	660	441 to 731	20	27.4	50	68.5	2	2.7	1	1.4
13q deletion status
Deleted	43	716	374 to 849	13	30.2	28	65.1	2	4.7	0	0.0
Normal	46	727	477 to 808	16	34.8	28	60.9	1	2.2	1	2.2

Abbreviations: CR, complete response; NE, not evaluated; PD, progressive disease; PFS, progression-free survival; PR, partial response.